BioE’s Multi-Lineage Progenitor Cell™ stem cell will be combined with Phillips Plastics’ growth structures.
BioE and Phillips Plastics will together develop and commercialize stem cell therapeutics for orthopedic applications. These stem cell therapeutics will consist of BioE’s Multi-Lineage Progenitor Cell™ (MLPC) stem cells derived from human umbilical cord blood and Phillips Plastics’ growth structures.
“The convergence of medical technologies in the form of biodevice combinations has enormous potential in the orthopedic sector,” points out Michael Haider, president and CEO for BioE.
In early development studies, the MLPC has differentiated into osteoblasts and chondrocytes along with numerous other cell and tissue precursors, BioE reports. Phillips Plastics is developing custom structures to enhance the growth of these cells from the MLPC.
“These therapeutics could lead to treatments for osteoporosis and bone fractures of the hip, spine, wrist, arm, and leg as well as remedies for injured or deteriorated joints throughout the body,” Haider adds.
